Skip to content
Optellum
  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case studies
    • Clinical Validation
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales
Menu Close
  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case studies
    • Clinical Validation
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales

News & Events

News in brief: innovations to tackle patient backlog and cancer care, first clinical use of accessible incubator

  • Post author:Rhiannon Lassiter
  • Post published:November 29, 2021
  • Post category:Media

Health Tech Newspaper

Read more articles

Previous PostGE Healthcare doubles down on AI with new product launches, partnerships with Optellum and Cambridge
Next PostOptellum and GE Healthcare to advance AI-powered lung cancer diagnosis

You Might Also Like

Read more about the article GE Healthcare, Optellum collaborate to advance lung cancer diagnosis with artificial intelligence

GE Healthcare, Optellum collaborate to advance lung cancer diagnosis with artificial intelligence

November 29, 2021
Read more about the article GE Healthcare and Optellum Join Forces to Advance Lung Cancer Diagnosis with Artificial Intelligence

GE Healthcare and Optellum Join Forces to Advance Lung Cancer Diagnosis with Artificial Intelligence

November 26, 2021
Read more about the article OPTELLUM TO COLLABORATE WITH JOHNSON & JOHNSON ON APPLYING AI TO TRANSFORM EARLY LUNG CANCER TREATMENT

OPTELLUM TO COLLABORATE WITH JOHNSON & JOHNSON ON APPLYING AI TO TRANSFORM EARLY LUNG CANCER TREATMENT

August 18, 2021
  • Back to News & Events

Recent Posts

  • How Optellum is working to change the survival rates for lung cancer with an innovative AI platform
  • Optellum welcomes ESTI back to Oxford for 2022 congress
  • PRESS RELEASE: CMS assigns new technology payment classification for Optellum’s Lung Cancer Prediction score
  • Optellum’s UK regulatory certification bolstered by UKCA marking for its early lung cancer diagnosis AI technology
  • Optellum is attending the 2022 ASCO Annual Meeting

Our Mission

Optellum was founded so that every lung disease patient is diagnosed and treated at the earliest possible stage, and cured.  Our vision is to redefine early intervention of diseases like lung cancer, by enabling every clinician, in every hospital, to make the right decisions and give their patients the best chance to fight back.

Optellum Ltd.

  • Oxford Centre for Innovation
    Oxford
    OX1 1BY
    United Kingdom
  • info@optellum.comOpens in your application

Optellum Inc.

  • TMC Innovation Institute
    2450 Holcombe Blvd, Suite X
    Houston, TX 77021
    United States

Follow Us

  • Opens in a new tab
  • Opens in a new tab

Pages

  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case studies
    • Clinical Validation
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales

Certifications

Copyright 2022 - Optellum Ltd | Privacy Policy
Manage Cookie Consent
We use cookies to optimize our website and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}